Baseline characteristics
| Variables at AML diagnosis, n (%) unless specified . | All patients (n = 104) . | Pre-HCT: FLT3-ITD positive∗ . | Pre-HCT: FLT3-ITD negative . | |
|---|---|---|---|---|
| PCR-NGS positive and CE positive (n = 7) . | PCR-NGS positive, CE negative (n = 29) . | PCR-NGS negative (n = 66) . | ||
| Median age (range), y | 49 (17-68) | 44 (25-68) | 51 (26-68) | 47 (17-68) |
| Men | 47 (45) | 1 (14) | 18 (62) | 27 (42) |
| AML subtype | ||||
| De novo | 97/102 (95) | 7 (100) | 26 (90) | 62/64 (97) |
| Secondary | 5/102 (5) | — | 3 (10) | 1/64 (3) |
| Prior therapy | ||||
| No FLT3 inhibitor | 76 (73) | 6 (86) | 18 (62) | 50 (76) |
| FLT3 inhibitor | 28 (27) | 1 (14) | 11 (38) | 16 (24) |
| Karyotype risk† | ||||
| Favorable | — | — | — | — |
| Intermediate | 95/96 (99) | 7/7 (100) | 28/28 (100) | 59/59 (100) |
| Adverse | 1/96 (1) | — | — | — |
| FLT3-ITD allelic ratio (1 NA) | ||||
| <0.5 | 59/103 (57) | 3 (43) | 15/28 (54) | 40 (61) |
| ≥0.5 | 44/103 (43) | 4 (57) | 13/28 (46) | 26 (39) |
| NPM1 mutant | 78 (75) | 4 (57) | 21 (72) | 52 (79) |
| NPM1 wild-type | 26 (25) | 3 (43) | 8 (28) | 14 (21) |
| FLT3-TKD mutant | 4/96 (4) | 0 | 2/28 (7) | 2/59 (3) |
| FLT3-TKD wild-type | 92/96 (96) | 7/7 (100) | 26/28 (93) | 57/59 (97) |
| DNMT3A mutant‡ | 33/59 (56) | 0 | 9/16 (56) | 23/40 (57) |
| DNMT3A wild-type | 26/59 (44) | 2/2 (100) | 7/16 (44) | 17/40 (43) |
| Prior lines of therapy pre-HCT | ||||
| 1 | 75 (72) | 2 (29) | 19 (66) | 52 (79) |
| 2 | 29 (28) | 5 (71) | 10 (34) | 14 (21) |
| Conditioning§ | ||||
| Myeloablative | 40/82 (49) | 3/6 (50) | 12/22 (55) | 24/53 (44) |
| Reduced intensity | 42/82 (51) | 3/6 (50) | 10/22 (45) | 29/52 (56) |
| Transplant status | ||||
| CR1 | 89 (86) | 3 (43) | 25 (86) | 59 (89) |
| CR2 | 15 (14) | 4 (57) | 4 (14) | 7 (11) |
| T-cell depletion‖ | 41/81 (51) | 4/5 (80) | 12/22 (54) | 25/53 (47) |
| Unrelated donor¶ | 52/100 (52) | 3/6 (50) | 9/28 (32) | 40/65 (62) |
| Median time from last treatment to day 0 of HCT (range), d | 42.5 (12-147) | |||
| Variables at AML diagnosis, n (%) unless specified . | All patients (n = 104) . | Pre-HCT: FLT3-ITD positive∗ . | Pre-HCT: FLT3-ITD negative . | |
|---|---|---|---|---|
| PCR-NGS positive and CE positive (n = 7) . | PCR-NGS positive, CE negative (n = 29) . | PCR-NGS negative (n = 66) . | ||
| Median age (range), y | 49 (17-68) | 44 (25-68) | 51 (26-68) | 47 (17-68) |
| Men | 47 (45) | 1 (14) | 18 (62) | 27 (42) |
| AML subtype | ||||
| De novo | 97/102 (95) | 7 (100) | 26 (90) | 62/64 (97) |
| Secondary | 5/102 (5) | — | 3 (10) | 1/64 (3) |
| Prior therapy | ||||
| No FLT3 inhibitor | 76 (73) | 6 (86) | 18 (62) | 50 (76) |
| FLT3 inhibitor | 28 (27) | 1 (14) | 11 (38) | 16 (24) |
| Karyotype risk† | ||||
| Favorable | — | — | — | — |
| Intermediate | 95/96 (99) | 7/7 (100) | 28/28 (100) | 59/59 (100) |
| Adverse | 1/96 (1) | — | — | — |
| FLT3-ITD allelic ratio (1 NA) | ||||
| <0.5 | 59/103 (57) | 3 (43) | 15/28 (54) | 40 (61) |
| ≥0.5 | 44/103 (43) | 4 (57) | 13/28 (46) | 26 (39) |
| NPM1 mutant | 78 (75) | 4 (57) | 21 (72) | 52 (79) |
| NPM1 wild-type | 26 (25) | 3 (43) | 8 (28) | 14 (21) |
| FLT3-TKD mutant | 4/96 (4) | 0 | 2/28 (7) | 2/59 (3) |
| FLT3-TKD wild-type | 92/96 (96) | 7/7 (100) | 26/28 (93) | 57/59 (97) |
| DNMT3A mutant‡ | 33/59 (56) | 0 | 9/16 (56) | 23/40 (57) |
| DNMT3A wild-type | 26/59 (44) | 2/2 (100) | 7/16 (44) | 17/40 (43) |
| Prior lines of therapy pre-HCT | ||||
| 1 | 75 (72) | 2 (29) | 19 (66) | 52 (79) |
| 2 | 29 (28) | 5 (71) | 10 (34) | 14 (21) |
| Conditioning§ | ||||
| Myeloablative | 40/82 (49) | 3/6 (50) | 12/22 (55) | 24/53 (44) |
| Reduced intensity | 42/82 (51) | 3/6 (50) | 10/22 (45) | 29/52 (56) |
| Transplant status | ||||
| CR1 | 89 (86) | 3 (43) | 25 (86) | 59 (89) |
| CR2 | 15 (14) | 4 (57) | 4 (14) | 7 (11) |
| T-cell depletion‖ | 41/81 (51) | 4/5 (80) | 12/22 (54) | 25/53 (47) |
| Unrelated donor¶ | 52/100 (52) | 3/6 (50) | 9/28 (32) | 40/65 (62) |
| Median time from last treatment to day 0 of HCT (range), d | 42.5 (12-147) | |||
NA, not available.
Two without available sample for CE correlation.
Determined according to UK MRC criteria. Eight patients with unknown karyotype.
DNMT3A mutation testing in 59 patients only.
Conditioning intensity information available in 82 patients. Myeloablative conditioning regimens were busulfan and cyclophosphamide, cyclophosphamide and total body irradiation, and fludarabine and 4 days of busulfan.
T-cell depletion information available in 81 patients.
Donor source information available in 100 patients.